Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:8541 |
Name | Sezary's disease |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | DOID:8790 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma peripheral T-cell lymphoma primary cutaneous T-cell non-Hodgkin lymphoma Sezary's disease |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01871727 | Phase III | E7777 | A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma | Completed | USA | 2 |
NCT02542124 | Phase II | Interleukin-12 | NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | Unknown status | USA | 0 |
NCT02581631 | Phase Ib/II | Brentuximab vedotin + Nivolumab | A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) | Completed | USA | ITA | FRA | ESP | CAN | 1 |
NCT02616965 | Phase I | Brentuximab vedotin + Romidepsin | A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02953301 | Phase II | Resminostat | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN) | Active, not recruiting | ITA | FRA | ESP | DEU | BEL | AUT | 6 |
NCT02978625 | Phase II | Nivolumab + Talimogene laherparepvec | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Recruiting | USA | 0 |
NCT03011814 | Phase Ib/II | Durvalumab Durvalumab + Lenalidomide | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | Recruiting | USA | 0 |
NCT03063632 | Phase II | Interferon gamma + Pembrolizumab | Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome | Active, not recruiting | USA | 0 |
NCT03081910 | Phase I | CD5 CAR T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT03385226 | Phase II | Pembrolizumab | A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT) | Active, not recruiting | 1 | |
NCT03587844 | Phase II | Brentuximab vedotin | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | Recruiting | USA | 0 |
NCT03602157 | Phase I | ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | Recruiting | USA | 0 |
NCT03695471 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | Recruiting | USA | 0 |
NCT03902184 | Phase II | Gemcitabine + Lacutamab + Oxaliplatin Lacutamab | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 1 |
NCT04185220 | Phase I | Mogamulizumab + rhIL-15 | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome | Completed | USA | 0 |
NCT04217317 | Phase II | Bendamustine + CPI-613 | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04234048 | Phase I | Fenretinide | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
NCT04256018 | Phase II | Mogamulizumab | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sezary Syndrome | Recruiting | USA | 0 |
NCT04401020 | Phase I | SAR442257 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | Recruiting | USA | ESP | 3 |
NCT04541017 | Phase Ib/II | Hu5F9-G4 Hu5F9-G4 + Mogamulizumab | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment | Recruiting | USA | 0 |
NCT04652960 | Phase I | Duvelisib + Nivolumab | Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome | Suspended | USA | 0 |
NCT04676087 | Phase Ib/II | Mogamulizumab | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | Recruiting | USA | 0 |
NCT04745234 | Phase II | Mogamulizumab | Mogamulizumab Q4week Dosing in Participants With R/R CTCL | Active, not recruiting | USA | ITA | FRA | ESP | 1 |
NCT04752826 | Phase Ib/II | BI-1808 + Pembrolizumab BI-1808 | BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20) | Recruiting | 4 | |
NCT04930653 | Phase II | Mogamulizumab | Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma | Recruiting | USA | 0 |
NCT04960618 | Phase II | Gemcitabine + Pembrolizumab | Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sezary Syndrome | Recruiting | USA | 0 |
NCT05079282 | Phase I | ONO-4685 | Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Recruiting | USA | 0 |